TMLI radiation therapy for haploidentical hematopoietic cell transplantation. (A) Study schema; patients received palifermin (60 µg/kg per day) for 3 days, starting on day −10 before stem cell infusion. PTCy was administered at 14.5 mg/kg per day on days −7 and −6. TMLI at the scheduled dose was delivered concurrently with fludarabine (25 mg/m² per day) for 5 days from day −7 to day −3. GvHD prophylaxis consisted of posttransplant cyclophosphamide (50 mg/kg per day) on days +3 and +4, GCSF (5 µg/kg) starting on day +5 and continued until >1500, and tacrolimus and mycophenolate mofetil starting on day +5 and continued until days +90 and +35, respectively. (B) TMLI dose levels and number of patients accrued at each dose level. (C) TMLI dose distribution colorwash map in a representative patient with AML who was treated at a TMLI dose of 2000 cGy. (D) Mean organ doses at each TMLI dose level for all patients (n = 31). G-CSF granulocyte colony stimulating factor